Global law firm White & Case LLP has advised Takeda Pharmaceutical Company Limited (Takeda) on its divestment of TAK-063 (Balipodect), a novel oral phosphodiesterase 10A (PDE10A) inhibitor for the treatment of schizophrenia and other neuropsychiatric conditions, to Axsome Therapeutics, Inc. (NASDAQ: AXSM).
Under the terms of the agreement, Axsome will acquire the worldwide commercial, development and manufacturing rights to Balipodect.
Takeda is a leading global biopharmaceutical company headquartered in Japan that is primarily focused on gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience. Axsome is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options.
The White & Case team which advised on the transaction was led by partners Leonardo Graffi (Milan & London), Michael Immordino (London & Milan) and Caitlin Powell Gimpel (Milan & New York) and included counsel Ajita Shukla (Washington, DC) and associate Mariasole Maschio (London) and lawyer Anna Sabatti (Milan).
Press contact
For more information please speak to your local media contact.
